• Filing Date: 2021-03-31
  • Form Type: 10-K
  • Description: Annual report
v3.21.1
Supplemental Cash Flow Information
12 Months Ended
Dec. 31, 2020
Supplemental Cash Flow Information [Abstract]  
Supplemental Cash Flow Information

NOTE 17 - SUPPLEMENTAL CASH FLOW INFORMATION

 

Supplemental cash flow information for the years ended December 31:

 

    2020     2019  
             
Cash paid for interest   $ 185,000     $ 128,000  
                 
Non-cash investing and financing activities:                
Impact of adoption of lease accounting standards   $ -     $ 1,616,000  
Gain from change in fair value of interest rate swap derivatives   $ -     $ 7,000  
Common stock issued upon conversion of convertible note   $ -     $ 500,000  
Equity issued to purchase intangible assets   $ -     $ 145,000  
Common A Shares issued for prepaid marketing services   $ 210,000     $ -  
Common A Shares issued for Impact BioMedical   $ 3,132,000     $ -  
Non-controlling interest related to Impact BioMedical   $ 3,910,000     $ -  
Series A Preferred Shares issued for Impact BioMedical   $ 35,187,000     $ -  
Notes receivable settled for assets in lieu of cash   $ 838,000     $ -